RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Carl Zeiss Meditec Stock

Carl Zeiss Meditec ROCE 2024

Carl Zeiss Meditec ROCE

0.16

Ticker

AFX.DE

ISIN

DE0005313704

WKN

531370

In 2024, Carl Zeiss Meditec's return on capital employed (ROCE) was 0.16, a -18.15% increase from the 0.2 ROCE in the previous year.

Carl Zeiss Meditec Aktienanalyse

What does Carl Zeiss Meditec do?

Carl Zeiss Meditec AG is a globally leading provider of medical technologies and devices for diagnostics and therapy. The company's history dates back to the founding of Carl Zeiss in 1846 in Jena, Germany. It has a long tradition in the development and manufacture of optical devices, particularly microscopes and binoculars. In 1996, Carl Zeiss decided to spin off its medical technology business segment and establish Carl Zeiss Meditec AG. Since then, the company has developed a wide portfolio of products used in ophthalmology and other medical fields. The business model of Carl Zeiss Meditec is based on three pillars: devices for diagnostics and therapy, software, and services. The devices are offered in various divisions specialized in specific application areas. The ophthalmology division is the largest and most well-known area of the company. It offers a wide range of diagnostic and therapy devices used in the treatment of eye diseases such as glaucoma, cataract, and retinal disorders. The products of the ophthalmology division include OCT systems (optical coherence tomography) for detailed examination of the retina, as well as VisuMax laser technology for correction of vision defects. Another important area of Carl Zeiss Meditec is the neurosurgery division. It offers devices for stereotactic neurosurgery used in the treatment of brain tumors, movement disorders, and other neurological conditions. The products of this division include the Kinevo stereotactic navigation system and the OPMI Neuro/NC4 surgical microscope series. In the dental division, Carl Zeiss Meditec provides innovative solutions for dentistry. This includes optical impression systems (Artemis), CAD/CAM systems, and dental microscopes. In addition to products, Carl Zeiss Meditec also offers software solutions for medical imaging and data processing. The FORUM software platform allows for intuitive management of medical images and findings. The company also provides training and education for doctors and medical professionals. The products of Carl Zeiss Meditec are known for their high quality, reliability, and precision. The company focuses on innovative technologies and continuously invests in research and development to strengthen its position as a market leader in the medical technology industry. Carl Zeiss Meditec is present in more than 60 countries worldwide and employs around 3,000 people. It is headquartered in Jena, Germany, and has additional locations in the United States, Canada, China, India, and other countries. Overall, Carl Zeiss Meditec AG is an innovative and reliable partner for the medical technology industry. Its wide range of products and services contributes to improving the health of millions of people worldwide. Carl Zeiss Meditec ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Carl Zeiss Meditec's Return on Capital Employed (ROCE)

Carl Zeiss Meditec's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Carl Zeiss Meditec's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Carl Zeiss Meditec's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Carl Zeiss Meditec’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Carl Zeiss Meditec stock

What is the ROCE (Return on Capital Employed) of Carl Zeiss Meditec this year?

The ROCE of Carl Zeiss Meditec is 0.16 undefined this year.

How has the ROCE (Return on Capital Employed) of Carl Zeiss Meditec developed compared to the previous year?

The ROCE of Carl Zeiss Meditec has increased by -18.15% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Carl Zeiss Meditec?

A high Return on Capital Employed (ROCE) indicates that Carl Zeiss Meditec has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Carl Zeiss Meditec?

A low ROCE (Return on Capital Employed) can indicate that Carl Zeiss Meditec has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Carl Zeiss Meditec impact the company?

An increase in the ROCE of Carl Zeiss Meditec can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Carl Zeiss Meditec affect the company?

A decrease in ROCE of Carl Zeiss Meditec can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Carl Zeiss Meditec?

Some factors that can affect Carl Zeiss Meditec's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Carl Zeiss Meditec so important for investors?

The ROCE of Carl Zeiss Meditec is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Carl Zeiss Meditec take to improve the ROCE?

To improve the ROCE, Carl Zeiss Meditec can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Carl Zeiss Meditec pay?

Over the past 12 months, Carl Zeiss Meditec paid a dividend of 1.1 EUR . This corresponds to a dividend yield of about 2.3 %. For the coming 12 months, Carl Zeiss Meditec is expected to pay a dividend of 1.22 EUR.

What is the dividend yield of Carl Zeiss Meditec?

The current dividend yield of Carl Zeiss Meditec is 2.3 %.

When does Carl Zeiss Meditec pay dividends?

Carl Zeiss Meditec pays a quarterly dividend. This is distributed in the months of April, April, April, April.

How secure is the dividend of Carl Zeiss Meditec?

Carl Zeiss Meditec paid dividends every year for the past 20 years.

What is the dividend of Carl Zeiss Meditec?

For the upcoming 12 months, dividends amounting to 1.22 EUR are expected. This corresponds to a dividend yield of 2.54 %.

In which sector is Carl Zeiss Meditec located?

Carl Zeiss Meditec is assigned to the 'Health' sector.

Wann musste ich die Aktien von Carl Zeiss Meditec kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Carl Zeiss Meditec from 3/26/2024 amounting to 1.1 EUR, you needed to have the stock in your portfolio before the ex-date on 3/22/2024.

When did Carl Zeiss Meditec pay the last dividend?

The last dividend was paid out on 3/26/2024.

What was the dividend of Carl Zeiss Meditec in the year 2023?

In the year 2023, Carl Zeiss Meditec distributed 0.9 EUR as dividends.

In which currency does Carl Zeiss Meditec pay out the dividend?

The dividends of Carl Zeiss Meditec are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Carl Zeiss Meditec stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank

Andere Kennzahlen von Carl Zeiss Meditec

Our stock analysis for Carl Zeiss Meditec Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Carl Zeiss Meditec Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.